METHODS OF TREATING KERATIN HYPERPROLIFERATION DISORDERS USING mTOR INHIBITORS

Abstract

A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.

1 . A method of treating psoriasis in a subject comprising:
 administering to the subject a therapeutically effective amount of an mTOR inhibitor selected from the group consisting of rapamycin (sirolimus), a rapamycin derivative, a rapamycin prodrug, and combinations thereof.   
     
     
         2 . The method of  claim 1 , wherein the rapamycin derivative is a member selected from the group consisting of: temsirolimus, everolimus, and combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the rapamycin prodrug is selected from the group consisting of AP-23573, AP-23481, and combinations thereof. 
     
     
         4 . The method of  claim 1 , wherein the mTOR inhibitor is rapamycin. 
     
     
         5 . The method of  claim 1 , wherein the mTOR inhibitor is a combination of two or more mTOR inhibitors. 
     
     
         6 . The method of  claim 1 , wherein the administration of the mTOR inhibitor is oral. 
     
     
         7 . The method of  claim 6 , wherein the mTOR inhibitor is administered in an amount from about 2 mg/day to about 20 mg/day. 
     
     
         8 . The method of  claim 1 , wherein the administration of the mTOR inhibitor is topical. 
     
     
         9 . The method of  claim 1 , wherein the administration of the mTOR inhibitor is transdermal. 
     
     
         10 . The method of  claim 1 , wherein the administration of the mTOR inhibitor is intravenous. 
     
     
         11 . The method of  claim 1 , wherein the administration of the mTOR inhibitor is both oral and topical. 
     
     
         12 . The method of  claim 11 , wherein the mTOR inhibitor administered orally is the same as the mTOR inhibitor administered topically. 
     
     
         13 . The method of  claim 11 , wherein the mTOR inhibitor administered orally is different from the mTOR inhibitor administered topically. 
     
     
         14 . The method of  claim 1 , wherein the administration of the mTOR inhibitor is both oral and transdermal. 
     
     
         15 . The method of  claim 14 , wherein the mTOR inhibitor administered orally is the same as the mTOR inhibitor administered transdermally. 
     
     
         16 . The method of  claim 14 , wherein the mTOR inhibitor administered orally is different from the mTOR inhibitor administered transdermally. 
     
     
         17 . The method of  claim 1 , wherein psoriasis results from an overexpression or inappropriate expression of a keratin encoded by a mRNA having a terminal oligopyrimidine (TOP) motif.